GB1498261A - Influenza vaccines - Google Patents
Influenza vaccinesInfo
- Publication number
- GB1498261A GB1498261A GB1290/75A GB129075A GB1498261A GB 1498261 A GB1498261 A GB 1498261A GB 1290/75 A GB1290/75 A GB 1290/75A GB 129075 A GB129075 A GB 129075A GB 1498261 A GB1498261 A GB 1498261A
- Authority
- GB
- United Kingdom
- Prior art keywords
- influenza
- components
- virus
- type
- cationic detergent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 229960003971 influenza vaccine Drugs 0.000 title abstract 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 abstract 6
- 125000002091 cationic group Chemical group 0.000 abstract 3
- 239000003599 detergent Substances 0.000 abstract 3
- 241000712461 unidentified influenza virus Species 0.000 abstract 3
- 241000700605 Viruses Species 0.000 abstract 2
- 206010022000 influenza Diseases 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 239000002245 particle Substances 0.000 abstract 2
- 230000006798 recombination Effects 0.000 abstract 2
- 238000005215 recombination Methods 0.000 abstract 2
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 abstract 1
- 229910019142 PO4 Inorganic materials 0.000 abstract 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 abstract 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 abstract 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 abstract 1
- 229940001007 aluminium phosphate Drugs 0.000 abstract 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 abstract 1
- 239000012736 aqueous medium Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000012141 concentrate Substances 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 239000000568 immunological adjuvant Substances 0.000 abstract 1
- 230000000415 inactivating effect Effects 0.000 abstract 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract 1
- 239000010452 phosphate Substances 0.000 abstract 1
- 239000002504 physiological saline solution Substances 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Detergent Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
1498261 Influenza vaccines SANDOZ Ltd 13 Jan 1975 [14 Jan 1974] 1290/75 Heading A5B The haemagglutinin and neuramuridase components are isolated from influenza virus by treating the virus in an aqueous medium with a cationic detergent to selectively solubilise such components, and separating the resulting solubilised such components from residual sub-viral particles. The virus concentrate may have a pH of from 6.5 to 8.5 and may inactivated with formaldehyde prior to the addition of the cationic detergent. After addition of the cationic detergent, the resulting mixture is preferably allowed to stand for 30 minutes to 16 hours at 4C to 37C. Influenza vaccines comprise a mixture of the haemagglutinin and neuramuridase components of an influenza virus, in the substantial absence of other components of the influenza viral particle in association with -an inertliquid diluent such as physiological saline optionally phosphate buffered. The vaccine may additionally comprise a preserving or inactivating agent such as formaldehyde and/or an immunological adjuvant such as aluminium hydroxide or aluminium phosphate. The influenza virus may be an influenza Type A, A 1 , A 2 or B virus, strain A2/Aichi/68, MRC-2 (recombination of Type A2/England/42/72), MRC-11 (recombination of Type A2/Port Chalmers/73), A/Pasteur/30C (Mutagrip), or B/Mass/67.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH44774A CH589453A5 (en) | 1974-01-14 | 1974-01-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB1498261A true GB1498261A (en) | 1978-01-18 |
Family
ID=4187233
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB1290/75A Expired GB1498261A (en) | 1974-01-14 | 1975-01-13 | Influenza vaccines |
Country Status (27)
| Country | Link |
|---|---|
| JP (2) | JPS58407B2 (en) |
| AT (1) | AT345449B (en) |
| AU (1) | AU500250B2 (en) |
| BE (1) | BE824372A (en) |
| CA (1) | CA1049406A (en) |
| CH (1) | CH589453A5 (en) |
| CS (1) | CS191254B2 (en) |
| DD (1) | DD116239A5 (en) |
| DE (1) | DE2500785B2 (en) |
| DK (1) | DK140003B (en) |
| ES (1) | ES433759A1 (en) |
| FI (1) | FI54053C (en) |
| FR (1) | FR2257305B1 (en) |
| GB (1) | GB1498261A (en) |
| HK (1) | HK56380A (en) |
| HU (1) | HU173920B (en) |
| IE (1) | IE40794B1 (en) |
| IL (1) | IL46426A (en) |
| MY (1) | MY8100204A (en) |
| NL (1) | NL166622C (en) |
| NO (1) | NO143128C (en) |
| PH (1) | PH14458A (en) |
| PL (1) | PL93689B1 (en) |
| SE (1) | SE427238B (en) |
| SU (1) | SU616997A3 (en) |
| YU (1) | YU41289B (en) |
| ZA (1) | ZA75259B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6793928B1 (en) | 1997-11-25 | 2004-09-21 | Duphar International Research Bv | Vaccines with an LTB adjuvant |
| WO2009029695A1 (en) * | 2007-08-28 | 2009-03-05 | Baxter International Inc. | Method for producing viral vaccines |
| WO2015071177A1 (en) | 2013-11-15 | 2015-05-21 | Novartis Ag | Removal of residual cell culture impurities |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2829089A1 (en) * | 1977-07-13 | 1979-02-01 | Sandoz Ag | SUBUNIT VACCINE |
| JPH0688911B2 (en) * | 1985-06-06 | 1994-11-09 | 国立予防衛生研究所長 | Influenza vaccine and method for producing the same |
| TW570803B (en) * | 1997-04-09 | 2004-01-11 | Duphar Int Res | Influenza vaccine |
| DE19938767C2 (en) * | 1999-08-16 | 2002-10-24 | Tad Pharma Gmbh | subunit vaccines |
| AU2006310171B2 (en) * | 2005-11-01 | 2011-02-17 | Seqirus UK Limited | Cell-derived viral vaccines with low levels of residual cell DNA by beta-propiolactone treatment |
-
1974
- 1974-01-14 CH CH44774A patent/CH589453A5/xx not_active IP Right Cessation
-
1975
- 1975-01-06 NO NO750031A patent/NO143128C/en unknown
- 1975-01-06 FI FI750014A patent/FI54053C/en not_active IP Right Cessation
- 1975-01-06 DK DK1475AA patent/DK140003B/en not_active IP Right Cessation
- 1975-01-07 SE SE7500130A patent/SE427238B/en not_active IP Right Cessation
- 1975-01-10 NL NL7500301.A patent/NL166622C/en not_active IP Right Cessation
- 1975-01-10 DE DE2500785A patent/DE2500785B2/en active Granted
- 1975-01-13 DD DD183614A patent/DD116239A5/xx unknown
- 1975-01-13 AT AT21475A patent/AT345449B/en not_active IP Right Cessation
- 1975-01-13 GB GB1290/75A patent/GB1498261A/en not_active Expired
- 1975-01-13 HU HU75SA2736A patent/HU173920B/en not_active IP Right Cessation
- 1975-01-13 PH PH16702A patent/PH14458A/en unknown
- 1975-01-13 IL IL46426A patent/IL46426A/en unknown
- 1975-01-13 PL PL1975177303A patent/PL93689B1/pl unknown
- 1975-01-13 CA CA217,790A patent/CA1049406A/en not_active Expired
- 1975-01-13 ES ES433759A patent/ES433759A1/en not_active Expired
- 1975-01-13 IE IE59/75A patent/IE40794B1/en unknown
- 1975-01-13 YU YU58/75A patent/YU41289B/en unknown
- 1975-01-14 CS CS75255A patent/CS191254B2/en unknown
- 1975-01-14 BE BE152368A patent/BE824372A/en not_active IP Right Cessation
- 1975-01-14 AU AU77305/75A patent/AU500250B2/en not_active Expired
- 1975-01-14 JP JP50006975A patent/JPS58407B2/en not_active Expired
- 1975-01-14 ZA ZA00750259A patent/ZA75259B/en unknown
- 1975-01-14 FR FR7501007A patent/FR2257305B1/fr not_active Expired
- 1975-01-14 SU SU752101722A patent/SU616997A3/en active
-
1980
- 1980-10-09 HK HK563/80A patent/HK56380A/en unknown
-
1981
- 1981-01-29 JP JP56012831A patent/JPS6035326B2/en not_active Expired
- 1981-12-30 MY MY204/81A patent/MY8100204A/en unknown
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6793928B1 (en) | 1997-11-25 | 2004-09-21 | Duphar International Research Bv | Vaccines with an LTB adjuvant |
| WO2009029695A1 (en) * | 2007-08-28 | 2009-03-05 | Baxter International Inc. | Method for producing viral vaccines |
| US8497112B2 (en) | 2007-08-28 | 2013-07-30 | Baxter International Inc. | Method for producing viral vaccines |
| RU2496519C2 (en) * | 2007-08-28 | 2013-10-27 | Бакстер Интернэшнл Инк. | Method for producing preparation containing viral antigens and using preparation |
| AU2008293513B2 (en) * | 2007-08-28 | 2013-11-21 | Nanotherapeutics, Inc. | Method for producing viral vaccines |
| WO2015071177A1 (en) | 2013-11-15 | 2015-05-21 | Novartis Ag | Removal of residual cell culture impurities |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2684792A (en) | Porcine reproductive respiratory syndrome vaccine and diagnostic | |
| BR9106374A (en) | ORAL VACCINE AND THE PROCESS OF EXTRACTING AN IMMUNORESPONSTA IN A MAMMAL | |
| GB1498261A (en) | Influenza vaccines | |
| AU6489986A (en) | Thymidine kinase deletion mutants of bovine herpersvirus-1, vaccines against infectious bovine rhinotracheitis containing same and methods for the production and use of same | |
| KR850001700A (en) | Method for preparing Herpes Simplex Virus Subuait Vaccine | |
| US3674864A (en) | Process for stabilizing preparations of interfering viruses | |
| Bang | Filamentous forms of Newcastle virus | |
| Russell et al. | Cell cooperation in antibody responses to influenza virus. I. Priming of helper T cells by internal components of the virion | |
| ES8104405A1 (en) | Influenza virus vaccines, process for preparing them and process for propagating influenza viruses. | |
| GB1292803A (en) | Improvements relating to the production of antigens | |
| ES471615A1 (en) | Glycoproteins from paramyxovirus and vaccines therefrom | |
| ES430415A1 (en) | Live influenza virus vaccines and preparation thereof | |
| Russell et al. | Mumps Viral Cytolysin: I. Action on Human Epithelial Cells in Tissue Culture | |
| GB1256457A (en) | Diethylaminoethyldextran (deae-d) as adjuvant for vaccines for active immunisation | |
| AU5573196A (en) | A pluripotent vaccine against enveloped viruses | |
| GB928807A (en) | Combined poliomyelitis-diphtheria-tetanus-pertussis antigen and methods for its manufacture | |
| GB953992A (en) | Vaccine products and method of preparing same | |
| GB1016586A (en) | Vaccine for immunization of dogs against distemper and hepatitis contagiosa canis | |
| Greer et al. | Electron microscope study of the interaction of vaccinia virus with macrophages from immunized and nonimmunized rabbits | |
| GB777018A (en) | Poliomyelitis vaccine products and methods for preparing the same | |
| Coggins et al. | Serological Comparison with Rabbit Antisera of Hog Cholera Virus and Bovine Virus Diarrhea Virus. | |
| PT100460A (en) | PARTICLES DERIVED FROM HERPES VIRUSES AND VACCINES THAT CONTAIN THEM | |
| GB1413401A (en) | Influenza vaccine | |
| 郭元吉 et al. | Influenza C virus isolated from pigs in China | |
| FR1246365A (en) | Process for the preparation of spheroidal shaped particles by suspension polymerization of ethylenic unsaturated monomers in aqueous medium |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PS | Patent sealed [section 19, patents act 1949] | ||
| 732 | Registration of transactions, instruments or events in the register (sect. 32/1977) | ||
| PCNP | Patent ceased through non-payment of renewal fee |
Effective date: 19940113 |